NDA 212576 · Taiho Oncology
Inqovi
Cedazuridine, Decitabine · Oral · Nucleoside Metabolic Inhibitor
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: May 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jul 7, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
80
3 Phase 3, 31 recruiting
FAERS reports
979
804 serious, 188 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 25, 2026.
INQOVI is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor, indicated: For treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. ( 1.1 ) In combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. ( 1.2 ) 1.1 Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. 1.2 Acute Myeloid Leukemia INQOVI is indicated in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Mechanism: Decitabine is a nucleoside metabolic inhibitor that is believed to exert its effects after phosphorylation and direct incorporation into DNA and inhibition of DNA methyltransferase, causing hypomethylation of DNA and cellular differentiation and/or apoptosis. Decitabine inhibits DNA methylation in vitro, which is achieved at concentrations that do not cause major suppression of DNA synthesis. Decitabine-induced hypomethylation in cancer cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the...
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 13, 2026 Supplement 8 · Efficacy OrphanLetterLabel
- Jul 7, 2020 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelOrphanLabelLetterReview
1 products under this application
- INQOVI · CEDAZURIDINE 100MG; DECITABINE 35MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cedazuridine" as an intervention, any sponsor and status, largest first.
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
- A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)Enrolling by invitation
Taiho Oncology, Inc.Industry
NCT04093570 · 332 participants (planned) · Start Sep 30, 2019 · Primary completion Dec 31, 2027
Drug: ASTX727 · For: Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes
Sites: Fountain Valley, California; Plantation, Florida; Chicago, Illinois · 47 sites in all
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)Pivotal-lookingRecruiting
Taiho Oncology, Inc.Industry
NCT04256317 · 316 participants (planned) · Start May 21, 2020 · Primary completion Nov 1, 2027
Drug: Azacitidine; ASTX030 (cedazuridine + azacitidine) and 4 more · For: Myelodysplastic Syndromes; Acute Myeloid Leukemia; Myelodysplastic Syndrome/Neoplasm and 1 more
Sites: Los Angeles, California; Orange, California; New Haven, Connecticut · 73 sites in all
Karyopharm Therapeutics IncIndustry
NCT02649790 · 277 participants (planned) · Start Jan 2016 · Primary completion Aug 31, 2024
Drug: KPT-8602; ASTX727 and 1 more · For: Relapsed/Refractory Multiple Myeloma (RRMM); Metastatic Colorectal Cancer (mCRC); Metastatic Castration-Resistant Prostate Cancer (mCRPC) and 3 more
Sites: Los Angeles, California; Pasadena, California; Aurora, Colorado · 46 sites in all
- Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AMLPivotal-lookingCompleted
Astex Pharmaceuticals, Inc.Industry
NCT03306264 · 227 participants · Start Feb 15, 2018 · Primary completion Sep 10, 2021
Drug: ASTX727; Dacogen · For: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia
Sites: Anniston, Alabama; Phoenix, Arizona; Tucson, Arizona · 84 sites in all
Washington University School of MedicineAcademic, hospital or other
NCT04742634 · 209 participants (planned) · Start May 12, 2022 · Primary completion Nov 30, 2033
Drug: DEC-C · For: Myelodysplastic Syndromes
Sites: St Louis, Missouri
- Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDSPivotal-lookingCompleted
Taiho Oncology, Inc.Industry
NCT03502668 · 160 participants · Start Jul 27, 2018 · Primary completion Jan 13, 2026
Drug: ASTX727 LD; ASTX727 SD · For: Myelodysplastic Syndromes
Sites: Birmingham, Alabama; Aurora, Colorado; New Haven, Connecticut · 29 sites in all
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative NeoplasmPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05600894 · 132 participants (planned) · Start Jun 27, 2023 · Primary completion Aug 31, 2027
Drug: Decitabine and Cedazuridine; Venetoclax · For: Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts and 2 more
Sites: Phoenix, Arizona; Costa Mesa, California; Irvine, California · 34 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue144
- inappropriate schedule of product administration142
- cytopenia129
- product use in unapproved indication120
- platelet count decreased115
- death114
- white blood cell count decreased92
- off label use78
- nausea73
- transfusion71
- haemoglobin decreased62
- asthenia58
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 26 |
| 2021 | 115 |
| 2022 | 64 |
| 2023 | 54 |
| 2024 | 137 |
| 2025 | 308 |
| 2026 | 275 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Inqovi (Decitabine/Cedazuridine)
2024 spending
$94.5M
Beneficiaries
2,928
12,036 claims
Per beneficiary
$32,276
$1,616.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,070,838 |
| 2021 | $53,167,043 |
| 2022 | $69,638,922 |
| 2023 | $77,261,469 |
| 2024 | $94,503,101 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.
Roboz GJ, Zeidan AM, Mannis GN, et al. · N Engl J Med 2026 · Multicenter Study, Clinical Trial, Phase II
- Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G, McCloskey J, Griffiths EA, et al. · Lancet Haematol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Bazinet A, Garcia-Manero G, Short N, et al. · Lancet Haematol 2024 · Clinical Trial, Phase II
- Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
Geissler K, Koristek Z, Del Castillo TB, et al. · Br J Haematol 2024 · Randomized Controlled Trial, Multicenter Study
- Oral decitabine-cedazuridine in acute myeloid leukaemia.
Bouligny IM, DiNardo CD · Br J Haematol 2024 · Randomized Controlled Trial
- FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes.
Kim N, Norsworthy KJ, Subramaniam S, et al. · Clin Cancer Res 2022 · Clinical Trial, Phase II
Sponsor: Taiho Oncology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.